Open AccessDelayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report
Author(s) -
Daniel Nan,
Cristina Abraira-Meriel,
Sandra de la Roz-Fernandez,
Tamara Maestre-Orozco,
José L. Hernández,
Marta FernándezAyala
Publication year - 2021
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2021_002821
Subject(s) - anakinra , medicine , ards , pulmonary fibrosis , pneumonia , refractory (planetary science) , covid-19 , fibrosis , respiratory distress , idiopathic pulmonary fibrosis , intensive care medicine , lung , disease , anesthesia , physics , astrobiology , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19 pneumonia in hospitalized patients with pulmonary fibrosis and refractory respiratory failure fulfilling ARDS criteria. The study demonstrates that anakinra has promising efficacy and safety in late-phase COVID-19 infection in patients with ARDS and refractory hypoxaemia, and suggests its potential application as antifibrotic therapy in these patients.